{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:42:49Z","timestamp":1790206969374,"version":"4.1.0"},"reference-count":72,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.clinthera.2011.12.003","type":"journal-article","created":{"date-parts":[[2012,1,30]],"date-time":"2012-01-30T05:46:57Z","timestamp":1327902417000},"page":"1-13","source":"Crossref","is-referenced-by-count":40,"title":["Fidaxomicin: The Newest Addition to the Armamentarium Against Clostridium difficile Infections"],"prefix":"10.1016","volume":"34","author":[{"given":"Jason W.","family":"Lancaster","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. James","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2011.12.003_bib1","series-title":"Dificid [package insert]","year":"2011"},{"key":"10.1016\/j.clinthera.2011.12.003_bib2","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1086\/510391","article-title":"A portrait of the geographic dissemination of the Clostridium difficile North American pulsed-field type 1 strain and the epidemiology of C. difficile-associated disease in Quebec","volume":"44","author":"Hubert","year":"2007","journal-title":"Clin Infect Dis"},{"issue":"Suppl 6","key":"10.1016\/j.clinthera.2011.12.003_bib3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1469-0691.2006.01580.x","article-title":"Emergence of Clostridium difficile-associated disease in North America and Europe","volume":"12","author":"Kuijper","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.clinthera.2011.12.003_bib4","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1056\/NEJMoa051639","article-title":"A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality","volume":"353","author":"Loo","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.12.003_bib5","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3201\/eid1203.051064","article-title":"Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996-2003","volume":"12","author":"McDonald","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib6","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1086\/502539","article-title":"A large outbreak of Clostridium difficile-associated disease with an unexpected proportion of deaths and colectomies at a teaching hospital following increased fluoroquinolone use","volume":"26","author":"Muto","year":"2005","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2807\/ese.13.31.18942-en","article-title":"Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008","volume":"13","author":"Kuijper","year":"2008","journal-title":"Euro Surveill"},{"key":"10.1016\/j.clinthera.2011.12.003_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.7326\/0003-4819-110-4-255","article-title":"Disease associated with Clostridium difficile infection","volume":"110","author":"Gerding","year":"1989","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.clinthera.2011.12.003_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/CMR.1.1.1","article-title":"Clostridium difficile: its disease and toxins","volume":"1","author":"Lyerly","year":"1988","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.clinthera.2011.12.003_bib10","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/0196-6553(86)90018-0","article-title":"Review of Clostridium difficile-associated diseases","volume":"14","author":"McFarland","year":"1986","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.clinthera.2011.12.003_bib11","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/BF02056938","article-title":"Clostridium difficile colitis in the critically ill","volume":"39","author":"Grundfest-Broniatowski","year":"1996","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.clinthera.2011.12.003_bib12","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/ageing\/28.2.107","article-title":"Factors associated with prolonged symptoms and severe disease due to Clostridium difficile","volume":"28","author":"Kyne","year":"1999","journal-title":"Age Ageing"},{"key":"10.1016\/j.clinthera.2011.12.003_bib13","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1086\/511793","article-title":"Clostridium difficile in the intensive care unit: epidemiology, costs, and colonization pressure","volume":"28","author":"Lawrence","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib14","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1086\/338260","article-title":"Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile","volume":"34","author":"Kyne","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1099\/jmm.0.45812-0","article-title":"Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhoea","volume":"54","author":"Ackermann","year":"2005","journal-title":"J Med Microbiol"},{"issue":"Suppl 4","key":"10.1016\/j.clinthera.2011.12.003_bib16","doi-asserted-by":"crossref","first-page":"S265","DOI":"10.1093\/clinids\/18.Supplement_4.S265","article-title":"Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism","volume":"18","author":"Bartlett","year":"1994","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib17","doi-asserted-by":"crossref","first-page":"122","DOI":"10.3201\/eid1501.080793","article-title":"Clostridium difficile-related hospitalizations among US adults, 2006","volume":"15","author":"Zilberberg","year":"2009","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib18","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1086\/522676","article-title":"The emerging infectious challenge of Clostridium difficile-associated disease in Massachusetts hospitals: clinical and economic consequences","volume":"28","author":"O'Brien","year":"2007","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib19","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.12.003_bib20","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1128\/JCM.42.5.1933-1939.2004","article-title":"Prevalence and characterization of a binary toxin (actin-specific adp-ribosyltransferase) from Clostridium difficile","volume":"42","author":"Goncalves","year":"2004","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib21","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(05)67420-X","article-title":"Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe","volume":"366","author":"Warny","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2011.12.003_bib22","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1086\/596703","article-title":"Health care-associated clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian nosocomial infection surveillance program study","volume":"48","author":"Gravel","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib23","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1086\/651706","article-title":"Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA)","volume":"31","author":"Cohen","year":"2010","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib24","series-title":"Vancocin [package insert]","year":"2005"},{"key":"10.1016\/j.clinthera.2011.12.003_bib25","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1503\/cmaj.1041104","article-title":"Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity","volume":"171","author":"Pepin","year":"2004","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2011.12.003_bib26","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1086\/519265","article-title":"A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity","volume":"45","author":"Zar","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib27","unstructured":"Louie T., Gerson M., Grimard D., et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-Associated Diarrhea (CDAD). Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17\u201320, 2007; Chicago, Ill."},{"key":"10.1016\/j.clinthera.2011.12.003_bib28","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/jac\/dkn313","article-title":"Emergence of reduced susceptibility to metronidazole in Clostridium difficile","volume":"62","author":"Baines","year":"2008","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib29","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1128\/AAC.00090-08","article-title":"Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease","volume":"52","author":"Al-Nassir","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib30","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1086\/592710","article-title":"Skin and environmental contamination with vancomycin-resistant enterococci in patients receiving oral metronidazole or oral vancomycin treatment for Clostridium difficile-associated disease","volume":"30","author":"Sethi","year":"2009","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib31","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1517\/13543776.2010.511177","article-title":"New antibiotics for selective treatment of gastrointestinal infection caused by Clostridium difficile","volume":"20","author":"Johnson","year":"2010","journal-title":"Expert Opin Ther Pat"},{"key":"10.1016\/j.clinthera.2011.12.003_bib32","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1097\/01.mcg.0000225685.37465.e7","article-title":"Efficacy of rifaximin and vancomycin combination therapy in a patient with refractory Clostridium difficile-associated diarrhea","volume":"41","author":"Berman","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib33","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1086\/599224","article-title":"Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection","volume":"48","author":"Herpers","year":"2009","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib34","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib35","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajic.2006.06.007","article-title":"Clinical outcomes of intravenous immune globulin in severe Clostridium difficile-associated diarrhea","volume":"35","author":"Juang","year":"2007","journal-title":"Am J Infect Control"},{"key":"10.1016\/j.clinthera.2011.12.003_bib36","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib37","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1093\/jac\/dkl553","article-title":"Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide","volume":"59","author":"Musher","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1086\/501126","article-title":"Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada","volume":"42","author":"Pepin","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib39","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7164\/antibiotics.28.253","article-title":"Lipiarmycin, a new antibiotic from actinoplanes","volume":"28","author":"Coronelli","year":"1975","journal-title":"J Antibiot"},{"key":"10.1016\/j.clinthera.2011.12.003_bib40","doi-asserted-by":"crossref","first-page":"247","DOI":"10.7164\/antibiotics.28.247","article-title":"Lipiarmycin, a new antibiotic from actinoplanes","volume":"28","author":"Parenti","year":"1975","journal-title":"J Antibiot"},{"key":"10.1016\/j.clinthera.2011.12.003_bib41","doi-asserted-by":"crossref","first-page":"543","DOI":"10.7164\/antibiotics.28.543","article-title":"Lipiarmycin, a new antibiotic from actinoplanes","volume":"28","author":"Sergio","year":"1975","journal-title":"J Antibiot"},{"key":"10.1016\/j.clinthera.2011.12.003_bib42","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1128\/AAC.50.1.401-402.2006","article-title":"Mutation in the bacillus subtilis RNA polymerase beta' subunit confers resistance to lipiarmycin","volume":"50","author":"Gualtieri","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib43","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1128\/JVI.33.3.945-953.1980","article-title":"Inhibition by lipiarmycin of bacteriophage growth in Bacillus subtilis","volume":"33","author":"Osburne","year":"1980","journal-title":"J Virol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib44","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1128\/AAC.48.6.2280-2282.2004","article-title":"In vitro activity of OPT-80 against Clostridium difficile","volume":"48","author":"Ackermann","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib45","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1128\/AAC.00104-11","article-title":"Postantibiotic effect of fidaxomicin and its major metabolite (OP-1118) against Clostridium difficile","volume":"55","author":"Babakhani","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib46","unstructured":"Babakhani F., Robert N., Shangle S., et al. Antimicrobial activity and post-antibiotic effect (PAE) of OPT-80, a new macrocyclic compound, against Clostridium difficile. Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29 -November 2, 2004; Washington, DC."},{"key":"10.1016\/j.clinthera.2011.12.003_bib47","unstructured":"Babakhani F., Seddon J., Robert N., et al. Narrow spectrum activity and low fecal protein binding of OPT-80 and its major hydrolysis metabolite (OP-1118). Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17-20, 2007; Chicago, Ill."},{"key":"10.1016\/j.clinthera.2011.12.003_bib48","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.anaerobe.2009.09.005","article-title":"Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection","volume":"15","author":"Citron","year":"2009","journal-title":"Anaerobe"},{"key":"10.1016\/j.clinthera.2011.12.003_bib49","doi-asserted-by":"crossref","first-page":"4430","DOI":"10.1128\/AAC.48.11.4430-4434.2004","article-title":"Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species","volume":"48","author":"Credito","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib50","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1128\/AAC.48.12.4898-4902.2004","article-title":"In vitro activities of OPT-80 and comparator drugs against intestinal bacteria","volume":"48","author":"Finegold","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib51","doi-asserted-by":"crossref","first-page":"2716","DOI":"10.1128\/AAC.01623-06","article-title":"In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004","volume":"51","author":"Hecht","year":"2007","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib52","unstructured":"Karlowsky J.A., Laing N.M., Alfa M., et al. In vitro antimicrobial activities of OPT-80, rifaximin, tigecycline, and comparators against toxin-positive Clostridium difficile cultured from diarrheal stool specimens. Abstract presented at: 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 17- 20, 2007; Chicago, Ill."},{"key":"10.1016\/j.clinthera.2011.12.003_bib53","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1099\/jmm.0.029470-0","article-title":"Killing kinetics of fidaxomicin and its major metabolite, OP-1118, against Clostridium difficile","volume":"60","author":"Babakhani","year":"2011","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.clinthera.2011.12.003_bib54","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1128\/AAC.00090-10","article-title":"In vitro activity of fidaxomicin (OPT-80) tested against contemporary clinical isolates of Staphylococcus spp. and Enterococcus spp","volume":"54","author":"Biedenbach","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib55","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1128\/AAC.01443-07","article-title":"OPT-80 eliminates Clostridium difficile and is sparing of bacteroides species during treatment of C","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib56","unstructured":"Nerandzic M.M., Mullane K.M., Miller M.A., et al. Acquisition and overgrowth of vancomycin-resistant enterococci in patients treated with either fidaxomicin (FDX) or vancomycin (VAN) for Clostridium difficile infection. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif."},{"key":"10.1016\/j.clinthera.2011.12.003_bib57","unstructured":"Babakhani F., Shangle S., Robert N., et al. Resistance development, crossresistance, and synergy studies of OPT-80. Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29-November 2, 2004; Washington, DC."},{"key":"10.1016\/j.clinthera.2011.12.003_bib58","unstructured":"Miller M., Mastrantonio P., Blanchette R., et al. Rifampin, rifaximin, OPT-80 and tigecycline susceptibility of C. difficile strains from Canada and Italy. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif."},{"key":"10.1016\/j.clinthera.2011.12.003_bib59","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1128\/AAC.35.6.1108","article-title":"In vitro and in vivo evaluation of tiacumicins b and c against Clostridium difficile","volume":"35","author":"Swanson","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib60","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1128\/AAC.01045-07","article-title":"Safety, tolerance, and pharmacokinetic studies of OPT-80 in healthy volunteers following single and multiple oral doses","volume":"52","author":"Shue","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib61","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1128\/AAC.01442-07","article-title":"Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection","volume":"53","author":"Louie","year":"2009","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib62","unstructured":"Louie T., Miller M., Crook D., et al. Effect of advancing age on outcomes of therapy for Clostridium difficile infection. Abstract presented at: Annual Scientific Meeting of the American Geriatrics Society; May 11-14, 2011; Washington, DC."},{"key":"10.1016\/j.clinthera.2011.12.003_bib63","unstructured":"Crook D., Weiss K., Cornely O.A., et al. Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin versus vancomycin. Abstract presented at: 20th European Congress of Clinical Microbiology and Infectious Diseases, April 10-13, 2010; Vienna, Austria."},{"key":"10.1016\/j.clinthera.2011.12.003_bib64","unstructured":"Mullane K., Golan Y., Crook D., et al. Renal impairment and response to fidaxomicin versus vancomycin in patients with clostridium difficile infection. Abstract presented at: 49th Annual meeting of the Infectious Diseases Society of America; October 20-23, 2011; Boston, Mass."},{"key":"10.1016\/j.clinthera.2011.12.003_bib65","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1056\/NEJMoa0910812","article-title":"Fidaxomicin versus vancomycin for Clostridium difficile infection","volume":"364","author":"Louie","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2011.12.003_bib66","unstructured":"Cheknis A.K., Citron D.M., Nagaro K.J., et al. Epidemic BI\/NAP1 is the dominant strain of Clostridium difficile found in patients in the OPT-80 vs. Vancomycin clinical trial in North American and the European Union. Abstract presented at: 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 25-28, 2008; Washington, DC."},{"key":"10.1016\/j.clinthera.2011.12.003_bib67","unstructured":"Golan Y., Mullane K.M., Miller M.A., et al. Low recurrence rate among patients with C. difficile infection (CDI) treated with fidaxomicin (FDX). Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif."},{"key":"10.1016\/j.clinthera.2011.12.003_bib68","unstructured":"Gorbach S., Weiss K., Sears P., et al. Safety of fidaxomicin versus vancomycin in treatment of Clostridium difficile infection. Abstract presented at: 49th Interscience Conference on Antimicrobial Agents and Chemotherapy; September 12-15, 2009; San Francisco, Calif."},{"key":"10.1016\/j.clinthera.2011.12.003_bib69","doi-asserted-by":"crossref","first-page":"5194","DOI":"10.1128\/AAC.00625-11","article-title":"Comparative susceptibilities of fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two fidaxomicin phase III trials of Clostridium difficile infection","volume":"55","author":"Goldstein","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.clinthera.2011.12.003_bib70","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/cid\/cir404","article-title":"Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections","volume":"53","author":"Mullane","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.clinthera.2011.12.003_bib71","unstructured":"Okumu F., Walsh R.B., Sears P., et al. Safety and pharmacokinetics of OPT- 80, a novel antibiotic for treatment of Clostridium difficile associated diarrhea (CDAD). Abstract presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; October 29-November 2, 2004; Washington, DC."},{"key":"10.1016\/j.clinthera.2011.12.003_bib72","series-title":"Drug Topics Red Book","year":"2011"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811008381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291811008381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,12,27]],"date-time":"2021-12-27T05:56:08Z","timestamp":1640584568000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291811008381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0149291811008381"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2011.12.003","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}